Rifampin (Synonyms: NIH 10782, NSC 113926, Rifampin) |
| رقم الكتالوجGC16305 |
ريفامبين هو مضاد حيوي فعال واسع المجال ضد الأمراض البكتيرية.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 13292-46-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens.
Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein[3].
Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration[1]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y[2].
References:
[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7.
[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2.
[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61.
|
Animal experiment: |
Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS® manifold, and imaged using an IVIS® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters. |
|
References: [1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. |
|
| Cas No. | 13292-46-1 | SDF | |
| المرادفات | NIH 10782, NSC 113926, Rifampin | ||
| Canonical SMILES | O[C@H]([C@H](C)[C@H]([C@H](/C=C/C=C(C)/C(NC1=C2O)=O)C)O)[C@@H](C)[C@@H]([C@H](C)[C@H](/C=C/O[C@@]3(C)OC4=C(C)C(O)=C2C(C(/C1=C/NN5CCN(C)CC5)=O)=C4C3=O)OC)OC(C)=O | ||
| Formula | C43H58N4O12 | M.Wt | 822.94 |
| الذوبان | ≥ 26.25mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2152 mL | 6.0758 mL | 12.1516 mL |
| 5 mM | 0.243 mL | 1.2152 mL | 2.4303 mL |
| 10 mM | 0.1215 mL | 0.6076 mL | 1.2152 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *